← Leaderboards
Alan D.t. Barrett
University Of Texas Medical Br Galveston
$16,202,275
Attributed
$16,202,275
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,202,275 · 9
By mechanism
N01$7,039,366 · 1
R01$2,236,930 · 3
U01$2,190,760 · 1
N02$1,977,099 · 1
T32$1,458,620 · 1
R21$1,299,500 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Scott C Weaver$56,593,623
- Elena I Frolova$7,924,153
- Ilya V. Frolov$8,182,660
- David H Walker$27,320,724
- Robert O. Fox$2,552,476
Others in their field
Top investigators on “Communicable Diseases”
- Jeffrey P Krischer · University Of South Florida$580,775,398
- Judith S. Currier · University Of California Los Angeles$277,419,428
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$240,302,862
- Melynda Holmes · Technical Resources Inc$231,847,503
- Lawrence Corey · Fred Hutchinson Cancer Center$228,424,910
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
Research focus
Communicable DiseasesAnimal ModelMouse ModelVirusStandardizationContractsEfficacy TestingVaccinesAttenuatedInfectionViralCulicidaeVirulenceGenomeAttenuationFutureVaccine DevelopmentPrototypeMutationMutantAmino Acid SubstitutionPhenotypeNucleotidesBase Sequence
Grant awards (43)
Role of nonstructural protein in limited genetic diversity of yellow fever 17D vaccine virus$240,000
R21 · FY2023 · AI · contact PI
Role of nonstructural protein in limited genetic diversity of yellow fever 17D vaccine virus$200,000
R21 · FY2022 · AI · contact PI
Preclinical development of candidate Zika virus vaccines using mouse models$237,000
R21 · FY2018 · AI · contact PI
Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus$633,348
N01 · FY2017 · AI · contact PI
Preclinical development of candidate Zika virus vaccines using mouse models$196,250
R21 · FY2017 · AI · contact PI
Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus$690,722
N01 · FY2016 · AI · contact PI
Next Generation sequencing of yellow fever 17D vaccine virus$232,500
R21 · FY2016 · AI · contact PI
TASK A74: Small Animal Screening Models to Assess New and Innovative Drug Candidates Against Bacillus Anthracis$850,223
N01 · FY2015 · AI · contact PI
Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus$845,987
N01 · FY2015 · AI · contact PI
Task A07: Diabetic Mouse Model for Proof-Of-Concept Testing$505,039
N01 · FY2015 · AI · contact PI
Next Generation sequencing of yellow fever 17D vaccine virus$193,750
R21 · FY2015 · AI · contact PI
Task A64: Mouse Models for Therapeutics Testing against Filoviruses$38,150
N01 · FY2015 · AI · contact PI
Task D04:World Reference Center for Emerging Viruses and Arboviruses$1,065,853
N01 · FY2014 · AI · contact PI
Task C12: Infectivity and Lethality of Filovirus strain(s) in NHP$848,083
N02 · FY2014 · AI · contact PI
Task A68: Refinement of small animal model potency assays for Filovirus challenge material$790,533
N02 · FY2014 · AI · contact PI
Task A07: Diabetic Mouse Model for Proof-Of-Concept Testing$505,039
N01 · FY2014 · AI · contact PI
Task A64: Mouse Models for Therapeutics Testing against Filoviruses$338,483
N02 · FY2014 · AI · contact PI
Emerging and Tropical Infectious Diseases$32,619
T32 · FY2014 · AI · contact PI
Emerging and Tropical Infectious Diseases$168,042
T32 · FY2013 · AI · contact PI
Emerging and Tropical Infectious Diseases$168,906
T32 · FY2012 · AI · contact PI
Task D03 World Reference Center for Emerging Viruses and Arboviruses$987,974
N01 · FY2011 · AI · contact PI
Task A20: Syrian Golden Hamster Model for Filoviruses$917,031
N01 · FY2011 · AI · contact PI
Emerging and Tropical Infectious Diseases$52,126
T32 · FY2011 · AI · contact PI
West Nile Virus: Epidemiology and Mosquito Competence$355,993
R01 · FY2010 · AI · contact PI
Emerging and Tropical Infectious Diseases$165,226
T32 · FY2010 · AI · contact PI
West Nile Virus: Epidemiology and Mosquito Competence$359,588
R01 · FY2009 · AI · contact PI
West Nile Virus: Epidemiology and Mosquito Competence$359,588
R01 · FY2008 · AI · contact PI
Anitviral Activity of Thioaptamers Against West Nile Virus$493,630
U01 · FY2007 · AI · contact PI
West Nile Virus: Epidemiology and Mosquito Competence$366,553
R01 · FY2007 · AI · contact PI
Emerging and Tropical Infectious Diseases$114,914
T32 · FY2007 · AI · contact PI
Anitviral Activity of Thioaptamers Against West Nile Virus$494,021
U01 · FY2006 · AI · contact PI
West Nile Virus: Epidemiology and Mosquito Competence$377,500
R01 · FY2006 · AI · contact PI
Emerging and Tropical Infectious Diseases$134,837
T32 · FY2006 · AI · contact PI
Anitviral Activity of Thioaptamers Against West Nile Virus$491,641
U01 · FY2005 · AI
Emerging and Tropical Infectious Diseases$139,483
T32 · FY2005 · AI
Anitviral Activity of Thioaptamers Against West Nile Virus$477,788
U01 · FY2004 · AI
Emerging and Tropical Infectious Diseases$143,176
T32 · FY2004 · AI
Anitviral Activity of Thioaptamers Against West Nile Virus$233,680
U01 · FY2003 · AI
Emerging and Tropical Infectious Diseases$138,628
T32 · FY2003 · AI
OVERWINTERING AND TRANSMISSION MECHANISMS OF SLE VIRUS$197,512
R01 · FY2001 · AI
EMERGING AND TROPICAL INFECTIOUS DISEASES$103,999
T32 · FY2001 · AI
MOLECULAR EPIDEMIOLOGY AND ECOLOGY OF OROPOUCHE VIRUS$220,196
R01 · FY2000 · AI
EMERGING AND TROPICAL INFECTIOUS DISEASES$96,664
T32 · FY2000 · AI